ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Core Viewpoint - ACELYRIN, INC. has determined that the unsolicited interest from Concentra Biosciences is not expected to yield a superior proposal compared to the planned all-stock merger with Alumis Inc, which is believed to maximize long-term value for ACELYRIN stockholders [1][2] Company Overview - ACELYRIN, INC. is a late-stage clinical biopharma company focused on developing transformative medicines in immunology, with its lead program being lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease treatment [4] Transaction Details - The all-stock transaction with Alumis is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [2] - ACELYRIN's Board of Directors continues to recommend that stockholders support the merger with Alumis [2] Advisory Information - Guggenheim Securities, LLC is serving as the financial advisor to ACELYRIN, while Fenwick & West LLP and Paul Hastings LLP are providing legal counsel [3]